A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a pivotal vote, the CDC's advisory committee has recommended the use of clesrovimab, a new monoclonal antibody, for infants under eight months to combat RSV, marking a significant advancement in public health.
